UK Bladder Cancer Market Projected to Reach $457.9 Million by 2035

UK bladder cancer market was valued at $276.9 million in 2025 and is projected to reach $457.9 million by 2035, growing at a CAGR of 5.2% during the forecast period (2026–2035). The UK bladder cancer market is evolving with the introduction of new treatment options that are reshaping clinical management and supporting overall market growth. Advancements in immunotherapy, targeted therapies, and combination regimens are expanding therapeutic choices across different stages of the disease. For instance, in November 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved BALVERSA (erdafitinib) for adults with unresectable or metastatic urothelial carcinoma harboring FGFR3 genetic alterations, following at least one prior PD-1 or PD-L1 inhibitor therapy. Approval was based on the Phase 3 THOR study, which showed median overall survival of 12.1 months with erdafitinib versus 7.8 months with chemotherapy, and progression-free survival of 5.6 months versus 2.7 months. The therapy provides a targeted precision treatment option for eligible bladder cancer patients in the UK. These innovations are particularly relevant given the persistent disease burden and the aging patient population in the UK. The integration of novel therapies into national treatment pathways is expected to enhance outcomes and increase demand for advanced oncology services.

Browse the full report description of “UK Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/uk-bladder-cancer-market

Bladder Cancer Mortality and Age-Related Burden in the UK

• In 2023, bladder cancer ranked as the 9th most common cause of cancer mortality in the UK, with approximately 5,800 fatalities annually.
• Mortality rates are higher among males, where it represents the 7th most common cause of cancer-related mortality.
• Nearly 56% of all newly diagnosed bladder cancer cases each year occur in individuals aged 75 and above.
• Mortality rates are highest among individuals aged 90 and over, accounting for approximately 15.7% of all bladder cancer-related fatalities during 2021–2023.

Therapeutic Advances and Regulatory Approvals in the UK Bladder Cancer Market

Market participants are focusing on expanding therapeutic options through regulatory approvals, innovative immunotherapies, and clinical research. Efforts are concentrated on advancing immune-based treatments and combination regimens to improve patient outcomes and provide new solutions for challenging non-muscle invasive bladder cancer cases.

• In July 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain patients with non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The approval, the first for ANKTIVA outside the United States, was supported by data from a single-arm, multicenter trial in which 77 evaluable patients received the therapy for up to 37 months.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Cancer Type
  • Diagnosis Method
  • Therapy
• Competitive Landscape - AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Company, Merck & Co., Inc., and Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Bladder Cancer Market Report Segment

Cancer Type 

• Transitional Cell Bladder Cancer/Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Others

Diagnosis Method

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (IVP)
• Others

By Therapy

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-bladder-cancer-market